Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
PierFranco Conte(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Roberto D’Amico(University of Modena and Reggio Emilia), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Michela Donadio(Azienda Ospedaliero Universitaria San Giovanni Battista), Giovanna Cavazzini(University of Padua), A.A. Brandes(Ospedale Bellaria), Sara Balduzzi(Dutch Cancer Society), Silvio Danese(IRCCS Ospedale San Raffaele), Giancarlo Bisagni, Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Luigi Cavanna(University of Pavia), A. Turletti(Ospedale Martini), Francesco Giotta(Istituto Tumori Bari), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Antonella Ferro(Ospedale Santa Chiara), O. Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Vittorio Gebbia(La Maddalena), Michele Aieta(Centro di Riferimento Oncologico della Basilicata)
Cited by 4
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k